The present application describes uses for and articles of manufacture including
Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending
progression free survival in a HER2-positive
breast cancer patient population; combining two HER2 antibodies to treat HER2-positive
cancer without increasing cardiac
toxicity; treating early-stage HER2-positive
breast cancer; treating HER2-positive
cancer by co-administering a mixture of
Pertuzumab and
Trastuzumab from the same
intravenous bag; treating HER2-positive metastatic gastric
cancer; treating HER2-positive
breast cancer with
Pertuzumab,
Trastuzumab and
Vinorelbine; treating HER2-positive breast cancer with Pertuzumab,
Trastuzumab and
aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or
fallopian tube cancer. It also describes an article of manufacture comprising a
vial with Pertuzumab therein and a
package insert providing safety and / or
efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.